Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma.

Mingdong Li,Chao Geng,Jinqu Hu,Shaowu Ou,Shengrong Long,Zan Wang

doi:10.18632/aging.102393

Abstract

Glioblastoma (GBM), a primary malignant tumor of the central nervous system, has a very poor prognosis. Analysis of global GBM samples has revealed a variety of long non-coding RNAs (lncRNAs) associated with prognosis; nevertheless, there remains a lack of accurate prognostic markers. Using RNA-Seq, methylation, copy number variation (CNV), mutation and clinical follow-up data for GBM patients from The Cancer Genome Atlas, we performed univariate analysis, multi-cluster analysis, differential analysis of different subtypes of lncRNA and coding genes, weighted gene co-expression network analyses, gene set enrichment analysis, Kyoto Encyclopedia of Genes and Genomes analysis, Gene Ontology analysis, and lncRNA CNV analyses. Our analyses yielded five lncRNAs closely related to survival and prognosis for GBM. To verify the predictive role of these five lncRNAs on the prognosis of GBM patients, the corresponding RNA-seq data from Chinese Glioma Genome Atlas were downloaded and analyzed, and comparable results were obtained. The role of one lncRNA LINC00152 has been observed previously; the others are novel findings. Expression of these lncRNAs could become effective predictors of survival and potential prognostic biomarkers for patients with GBM.

Highlights

GBM is one of the most common primary malignant tumors of the central nervous system, accounting for 47.1% of all brain malignant tumors
We speculated that differential expression and copy number variation (CNV) of long non-coding RNAs (lncRNAs) may serve as prognostic biomarkers for patients with GBM
A lncRNA-PCG co-expression module was identified in GBM patients

Summary

Introduction

GBM is one of the most common primary malignant tumors of the central nervous system, accounting for 47.1% of all brain malignant tumors. Information from the Central Brain Tumor Registry of the United States (CBTRUS) revealed that the incidence of malignant brain tumors increases with age (the highest incidence is in the over 85 years old age group [85.39 per 100,000 people]), while the lowest incidence is in children and adolescents aged 0–19 years old [5.76 per 100,000]. The incidence of GBM in the United States is about (3.20 per 100,000) [1] and the age of onset is mostly in the range of 45–70 years old. Standardized treatment options for GBM include surgical excision within the maximum safe range, post-operative adjuvant radiotherapy, and chemotherapy, most commonly with temozolomide, a cytotoxic alkylator

Objectives

Methods

Results

Conclusion